UnitedHealth Groupの空売り状況は、投資家がUnitedHealth Groupの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

UnitedHealth Group (NYSE:UNH) 株価情報, 空売り情報

UnitedHealth Group

UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

UnitedHealth Group Incorporated Common Stock (DE)

UnitedHealth Group Inc

EC Healthcare

United Hampshire US REIT

WIIM

Shares of health insurance stocks are trading higher in possible reaction to President-elect Donald Trump indicating he plans to nominate Dr. Mehmet Oz as administrator for the Centers for Medicare and Medicaid Services. Oz has reportedly supported Medicare Advantage plans.

The Federal Trade Commission (FTC) is facing legal challenges from three competing pharmacy-benefit managers (PBMs) over its attempt to restrict their ability to negotiate drug prices for <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41256923/cvs-unitedhealth-request-ftc-chair-recusal-amid-ongoing-pharmacy-benefit-managers-lawsuit" rel="noreferrer noopener">health plan sponsors</a>.
In September, the FTC filed a formal complaint against three major pharmacy benefit managers (PBMs)—CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) Caremark,&nbsp;Cigna Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), Express Scripts, and&nbsp;UnitedHealth Group Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) Optum—for allegedly engaging in unfair and anti-competitive practices that have inflated the list&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/07/39695378/ftc-investigation-uncovers-anti-competitive-practices-by-handful-of-pharmacy-benefit-managers-includ" rel="noreferrer noopener">price of insulin medications</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The&nbsp;complaint&nbsp;accuses the PBMs of creating a system that benefits them financially by prioritizing drug rebates, forcing patients to pay higher costs for life-saving insulin. These PBMs, referred to as the Big Three, administer around 80% of <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">prescriptions in the U.S</a>.
The PBMs argue that this action seeks to upend current drug rebate contracts and disrupt long-standing practices, all while expanding the FTC&#8217;s authority beyond traditional limits.
The companies also <a target="_blank" href="https://www.bloomberglaw.com/public/desktop/document/ExpressScriptsIncetalvFederalTradeCommissionetalDocketNo424cv0154?doc_id=X11H3MUIQJ4995RQ9NSUPGSE2AP" rel="noreferrer noopener">contend</a> that the administrative proceeding violates constitutional principles by lacking independent judicial oversight and claim that the FTC&#8217;s approach could result in significant and irreparable injury.
The lawsuit stems from the FTC&#8217;s attempt to regulate the drug rebate system, allowing PBMs to secure manufacturers&#8217; discounts.
However, the FTC&#8217;s complaint accuses the PBMs of using their power to create an unfair market, alleging that the system allows drug manufacturers to inflate prices.
In challenging the FTC&#8217;s action, the PBMs argue that this is not just a market dispute but a constitutional issue.
They assert that the FTC&#8217;s administrative proceeding, taking place in an in-house forum where the agency decides the facts, the law, and the outcome, is unconstitutional.
Furthermore, the PBMs argue that the FTC&#8217;s decision to handle the case through this in-house process, with a partisan panel of Democratic commissioners, deprives them of a fair trial.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42094248/trumps-return-boosts-palantir-national-security-bets-drive-140-billion-market-cap" target="_blank" rel="noreferrer noopener">Palantir Tech&#8217;s $140 Billion Market Cap Gain Is Driven By Trump&#8217;s Victory And Higher Defense Spending Hope &#8211; Is The Stock Overvalued?</a></li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Government

Large Cap

News

Regulations

Health Care

Legal

General

Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System

<a href="https://news.bloomberglaw.com/antitrust/cvs-cigna-unitedhealth-sue-to-block-ftc-case-on-insulin-costs">https://news.bloomberglaw.com/antitrust/cvs-cigna-unitedhealth-sue-to-block-ftc-case-on-insulin-costs</a>
&nbsp;

Reported November 19, 2024 "CVS, Cigna, UnitedHealth Sue To Nix FTC Case On Insulin Cost" - Bloomberg Law

President-elect Donald Trump on Tuesday said he will nominate celebrity physician Dr. Mehmet Oz to lead the Centers for <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Medicare and Medicaid Services (CMS). </a>
The Details: Trump announced Dr. Oz as his pick for CMS administrator in a statement Tuesday afternoon.&nbsp;
"Our broken Healthcare System harms everyday Americans, and crushes our country's budget," Trump said.&nbsp;
"Dr. Oz will be a leader in incentivizing disease prevention, so we get the best results in the world for every dollar we spend on health care in our Great Country," Trump said. "He will also cut waste and fraud within our country's most expensive government agency, which is a third of our nation's health care spend, and a quarter of our entire national budget."
Read More: <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a>
Dr. Oz has a history of offering unproven medical advice and has said his goal was to "empower" Americans to take control of their health, according to the New York Times. He <a href="https://www.nytimes.com/2021/12/26/us/politics/dr-oz-medical-advice.html">promoted the use</a> of hydroxychloroquine as an effective treatment against COVID-19 in the early days of the pandemic, before reversing course and advising patients to wait for evidence from randomized trials.&nbsp;
CMS, an agency within the Health and Human Services Department (HHS), oversees several major health care programs including Medicare, Medicaid, the Children's Health Insurance Program and the Healthcare.gov insurance marketplace exchange. Federal spending on the four programs is $1.6 trillion, or nearly 25% of the entire federal budget.
Last week, Trump announced his intention to nominate another <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">controversial figure,</a> Robert Kennedy Jr., to head the HHS.&nbsp; Other unconventional selections include Trump's choices of former Rep. Matt Gaetz for U.S. attorney general and Fox News host Pete Hegseth for defense secretary.
Chiquita Brooks-LaSure is the current CMS administrator under the Biden administration.&nbsp;
Following Trump&#8217;s announcement, investors may want to monitor shares of UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), the largest Medicare Advantage insurer nationwide, and shares of Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), one of the largest Medicaid insurers.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: G. Holland via Shutterstock

Politics

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Trump Picks Dr. Oz As Centers For Medicare And Medicaid Services Administrator

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares have declined 5.3% over the past week as the company faces a significant legal challenge to its <a href="https://www.benzinga.com/news/legal/24/11/41917050/justice-department-moves-to-block-unitedhealths-amedisys-takeover-whats-going-on">$3.3 billion acquisition</a> of Amedisys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>).
What To Know: The U.S. Justice Department, along with attorneys general from multiple states, has recently filed a lawsuit to block the deal, citing antitrust concerns in the home health services sector. 
The agency argues the merger could lead to higher healthcare costs, particularly as Amedisys is a direct competitor to UnitedHealth&#8217;s LHC Group, which was acquired for $5.4 billion in 2022.
The Justice Department contends that allowing the merger would tighten UnitedHealth&#8217;s control over the home health and hospice care market, potentially disadvantaging seniors and caregivers. 
In response, UnitedHealth and Amedisys have proposed selling assets to VitalCaring Group to address these concerns, but negotiations have yet to alleviate regulatory resistance.
UnitedHealth's Optum unit has actively <a href="https://www.benzinga.com/general/health-care/24/11/41987383/unitedhealths-optum-defends-multi-billion-dollar-amedisys-deal-ensures-competitive-landscape">defended the merger</a>, emphasizing the fragmented nature of the home healthcare industry and its potential to address the growing demand for elder care as the U.S. population ages. However, skepticism persists as analysts and regulators scrutinize the impact on market competition.
Read Also: <a href="https://www.benzinga.com/news/events/24/11/42069387/grant-cardone-calls-himself-a-coward-investor-puts-his-money-in-real-assets">Grant Cardone Calls Himself A &#8216;Coward Investor,&#8217; Puts His Money In &#8216;Real Assets&#8217;</a>
<h2 class="wp-block-heading">How To Buy UNH Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in UnitedHealth Group&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, UNH has a 52-week high of $630.73 and a 52-week low of $436.38.

AMED

What's Going On With UnitedHealth Stock?

High-rolling investors have positioned themselves bearish on UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in UNH often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 20 options trades for UnitedHealth Group. This is not a typical pattern.
The sentiment among these major traders is split, with 10% bullish and 75% bearish. Among all the options we identified, there was one put, amounting to $29,218, and 19 calls, totaling $691,985.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $595.0 to $650.0 for UnitedHealth Group over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for UnitedHealth Group options trades today is 516.5 with a total volume of 1,290.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for UnitedHealth Group's big money trades within a strike price range of $595.0 to $650.0 over the last 30 days.
<h3>UnitedHealth Group Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732038353_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$11.25</td>
<td>$10.35</td>
<td>$10.8</td>
<td>$650.00</td>
<td>$54.0K</td>
<td>394</td>
<td align="right">50</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.15</td>
<td>$7.9</td>
<td>$8.0</td>
<td>$600.00</td>
<td>$49.6K</td>
<td>1.3K</td>
<td align="right">226</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$26.3</td>
<td>$26.1</td>
<td>$26.3</td>
<td>$600.00</td>
<td>$47.3K</td>
<td>707</td>
<td align="right">40</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.2</td>
<td>$8.8</td>
<td>$9.0</td>
<td>$600.00</td>
<td>$44.1K</td>
<td>1.3K</td>
<td align="right">52</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$8.2</td>
<td>$7.85</td>
<td>$8.0</td>
<td>$600.00</td>
<td>$40.0K</td>
<td>1.3K</td>
<td align="right">226</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<h3>Current Position of UnitedHealth Group</h3>
<ul>
<li>Trading volume stands at 998,091, with UNH's price down by -1.4%, positioned at $581.39.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 52 days.</li>
</ul>
<h3>Professional Analyst Ratings for UnitedHealth Group</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $603.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $603. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for UnitedHealth Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

Unpacking the Latest Options Trading Trends in UnitedHealth Group

UnitedHealth Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) short percent of float has fallen 8.33% since its last report. The company recently reported that it has 7.06 million shares sold short, which is 0.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>UnitedHealth Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731690918_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UnitedHealth Group has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing UnitedHealth Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UnitedHealth Group's peer group average for short interest as a percentage of float is 4.90%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(UNH) - Analyzing UnitedHealth Group's Short Interest

On Tuesday, the U.S. Justice Department said it will block UnitedHealth Group Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) multi-billion&nbsp;acquisition of&nbsp;Amedisys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>).
The Justice Department has sued to block UnitedHealth&#8217;s $3.3 billion purchase of healthcare services company Amedisys, citing concerns about competition in the home <a target="_blank" href="https://www.benzinga.com/news/legal/24/11/41917050/justice-department-moves-to-block-unitedhealths-amedisys-takeover-whats-going-on" rel="noreferrer noopener">health services market</a>.
UnitedHealth&#8217;s Optum unit&nbsp;launched a website&nbsp;that aims to highlight the benefits of the combination. The website <a target="_blank" href="https://www.improvinghomecare.com/" rel="noreferrer noopener">notes</a> that the home healthcare industry remains highly fragmented despite the growing market.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
On average, 26 agencies compete in metropolitan areas with about 500,000 residents, highlighting the range of available care options.
In 2020, approximately 3 million Americans received home health care, a figure expected to grow as the population ages.
By 2030, 18% of the U.S. population will be 65 or older, a significant increase from 13% in 2021.
This demographic shift underscores the necessity for expanded home health services that allow older adults to remain in their homes.
The merger between Optum and Amedisys represents a strategic move to address these needs.
While this combined entity would represent only a portion of the overall home health and hospice care market, the competitive landscape is expected to remain robust.
To promote competition and prevent market dominance, Optum and Amedisys have agreed to divest numerous home health and hospice centers to VitalCaring upon the transaction&#8217;s completion.
VitalCaring currently operates at around 58 locations across six states.
Price Action: UNH stock is down 2.76% at $589.17 at the last check Thursday
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41979149/general-motors-faces-recall-crisis-with-faulty-transmissions-details" target="_blank" rel="noreferrer noopener">General Motors Faces Recall Crisis With Faulty Transmissions: Details</a></li>
</ul>
Image via Shutterstock

UnitedHealth's Optum Defends Multi-Billion Dollar Amedisys Deal, Ensures Competitive Landscape

AMZN

AVGO

CPAY

TTWO

Tiger Global 13F Shows Increased Stake In UnitedHealth Group From 2,347,600 To 2,365,400 Shares; Amazon From 6,321,080 To 6,415,488 Shares; Take-Two Interactive Software From 5,643,542 To 5,839,256 Shares; Eli Lilly & Co From 930,000 To 969,800 Shares; Taiwan Semiconductor Manufacturing From 3,070,890 To 3,634,980 Shares; Corpay From 1,046,600 To 1,247,577 Shares; Broadcom From 182,300 To 1,845,500 Shares

UnitedHealth Says 'Will Vigorously Defend Against The DOJ's Overreaching'

UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) shares are trading lower Tuesday. The U.S. Justice Department is moving to block the company&#8217;s multi-billion <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/06/32716991/optums-decision-to-target-amedisys-is-intriguing-says-analyst">acquisition of Amedisys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>)</a>.
What To Know: The Justice Department has sued to block UnitedHealth&#8217;s $3.3 billion purchase of healthcare services company Amedisys, citing concerns related to competition in the home health services market, according to <a href="https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738">The Wall Street Journal</a>.
Antitrust enforcers are concerned that a potential business combination could cause healthcare price increases in the areas where Amedisys competes with UnitedHealth's LHC Group.
&#8220;Unless this $3.3 billion transaction is stopped, UnitedHealth Group will further extend its grip to home health and hospice care, threatening seniors, their families and nurses," Assistant Attorney General&nbsp;Jonathan Kanter&nbsp;said.
The Justice Department reportedly filed the complaint in Maryland federal court, supported by state attorneys general of Maryland, Illinois, New Jersey and New York. 
The report indicates that UnitedHealth and Amedisys executives met with the Justice Department last week, aiming to ease concerns. The companies proposed selling some of their other assets to VitalCaring Group.
See Also: <a href="https://www.benzinga.com/news/global/24/11/41912971/stocks-fall-on-tariffs-fears-dollar-hits-6-month-peak-yen-tumbles-whats-driving-markets-tuesday">Stocks Fall On Tariffs Fears, Dollar Hits 6-Month Peak, Yen Tumbles: What&#8217;s Driving Markets Tuesday?</a>
UnitedHealth entered into an agreement to acquire Amedisys last year. At the time, analysts raised concerns that the deal was likely to face scrutiny given the company&#8217;s robust home healthcare presence.
United Health bought LHC Group for about $5.4 billion in 2022. Amedisys is a main competitor&nbsp;to UnitedHealth&#8217;s LHC Group. Amedisys shares were down 2.21% at $90.54 at last check.
UNH Price Action: UnitedHealth shares were down 1.18% at $617.85 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of UnitedHealth.

Movers

Justice Department Moves To Block UnitedHealth's Amedisys Takeover: What's Going On?

<a href="https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738?mod=latest_headlines">https://www.wsj.com/business/justice-department-sues-to-block-unitedhealths-3-3-billion-bid-for-amedisys-b0b1f738?mod=latest_headlines</a>
&nbsp;
The Justice Department on Tuesday sued to block <a href="https://www.wsj.com/market-data/quotes/UNH">UnitedHealth Group</a>'s $3.3 billion acquisition of <a href="https://www.wsj.com/market-data/quotes/AMED">Amedisys</a> alleging the deal would give the <a href="https://www.wsj.com/health/healthcare/unitedhealth-shares-dive-after-health-giant-says-2025-results-likely-to-fall-short-8a7ff76a?mod=article_inline">health-industry giant</a> too much power over the market for home health and hospice services.
The government's move represents an effort to stem the roll-up of different healthcare services under a single owner. UnitedHealth last year acquired one of Amedisys's major competitors, LHC Group.&nbsp;

"Justice Department Sues To Block UnitedHealth's $3.3B Bid For Amedisys; Antitrust Enforcers Argue The Healthcare Giant's Latest Deal Would Illegally Harm Competition" - WSJ

Financial giants have made a conspicuous bullish move on UnitedHealth Group. Our analysis of options history for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) revealed 28 unusual trades.
Delving into the details, we found 50% of traders were bullish, while 32% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $160,867, and 24 were calls, valued at $6,833,141.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $240.0 to $720.0 for UnitedHealth Group over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in UnitedHealth Group's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to UnitedHealth Group's substantial trades, within a strike price spectrum from $240.0 to $720.0 over the preceding 30 days.
<h3>UnitedHealth Group 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731434474_0_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$378.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$1.1M</td>
<td>6.0K</td>
<td align="right">30</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">300</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">275</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">250</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$382.0</td>
<td>$377.1</td>
<td>$382.0</td>
<td>$240.00</td>
<td>$955.0K</td>
<td>6.0K</td>
<td align="right">225</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
In light of the recent options history for UnitedHealth Group, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>UnitedHealth Group's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,193,221, with UNH's price down by -1.11%, positioned at $618.3.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 59 days.</li>
</ul>
<h3>What The Experts Say On UnitedHealth Group</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $616.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Truist Securities lowers its rating to Buy with a new price target of $625. 
&#x2A; An analyst from Morgan Stanley has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $610. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on UnitedHealth Group, which currently sits at a price target of $650. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for UnitedHealth Group, targeting a price of $595. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on UnitedHealth Group with a target price of $603. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest UnitedHealth Group options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Behind the Scenes of UnitedHealth Group's Latest Options Trends

Financial giants have made a conspicuous bullish move on UnitedHealth Group. Our analysis of options history for UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) revealed 13 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 15% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $146,790, and 9 were calls, valued at $431,920.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $300.0 to $640.0 for UnitedHealth Group during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for UnitedHealth Group's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across UnitedHealth Group's significant trades, within a strike price range of $300.0 to $640.0, over the past month.
<h3>UnitedHealth Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731337236_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$121.7</td>
<td>$116.45</td>
<td>$120.0</td>
<td>$550.00</td>
<td>$84.0K</td>
<td>173</td>
<td>7</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.35</td>
<td>$5.85</td>
<td>$6.35</td>
<td>$630.00</td>
<td>$63.0K</td>
<td>4.4K</td>
<td>2.9K</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$37.35</td>
<td>$34.95</td>
<td>$36.24</td>
<td>$600.00</td>
<td>$54.3K</td>
<td>1.3K</td>
<td>39</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$37.4</td>
<td>$34.9</td>
<td>$36.23</td>
<td>$600.00</td>
<td>$54.3K</td>
<td>1.3K</td>
<td>24</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$122.3</td>
<td>$119.2</td>
<td>$122.3</td>
<td>$500.00</td>
<td>$48.9K</td>
<td>2.0K</td>
<td>4</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
In light of the recent options history for UnitedHealth Group, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of UnitedHealth Group</h3>
<ul>
<li>With a volume of 206,951, the price of UNH is up 1.22% at $623.31. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 60 days.</li>
</ul>
<h3>Expert Opinions on UnitedHealth Group</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $627.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Truist Securities downgraded its rating to Buy, setting a price target of $625. 
&#x2A; Maintaining their stance, an analyst from TD Cowen continues to hold a Buy rating for UnitedHealth Group, targeting a price of $609. 
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $650. 
&#x2A; An analyst from Stephens &amp; Co. has decided to maintain their Overweight rating on UnitedHealth Group, which currently sits at a price target of $605. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on UnitedHealth Group, which currently sits at a price target of $650. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for UnitedHealth Group with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

On Wednesday, Donald Trump, the Republican candidate and former president, was elected to the highest office again, marking a return to an administration. His second term is likely to impact U.S. healthcare.
Trump has been unclear about his healthcare policy goals during his campaign. Healthcare <a target="_blank" href="https://www.kff.org/health-care-in-2024-elections-apvotecast-polling/?entry=kff-analysis-of-ap-votecast-abortion-ballot-initiatives" rel="noreferrer noopener">ranked</a> lower than issues like the economy and immigration in voter concerns.
A <a target="_blank" href="https://apnews.com/article/ap-votecast-elections-harris-trump-voters-d5cf4e3611f50ec4349d93ddc7f037cd" rel="noreferrer noopener">poll</a> from the Associated Press found that only 8% of voters viewed healthcare as their top issue, compared to 39% who chose the economy and 20% who picked immigration. Abortion was the leading issue for 11% of voters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Despite his focus on &#8220;Make America Healthy Again,&#8221; millions of Americans may lose health insurance subsidies next year, depending on the political climate after the election and the Republicans&#8217; control of the Senate.
The subsidies, expanded under the 2021 American Rescue Plan, help many, particularly the middle class, afford health insurance through the Affordable Care Act (ACA).
These subsidies are set to expire at the end of 2025, and it remains uncertain whether they will be extended under the new administration.
Trump and other Republicans have opposed continuing the subsidies.
The NBC News <a target="_blank" href="https://www.nbcnews.com/health/health-news/millions-risk-losing-health-insurance-trumps-victory-rcna179146" rel="noreferrer noopener">report</a>, citing some analysts, suggests that the chances of extension could be less than 5% if Republicans win control of the House and the Senate.
Even if Democrats control the House, extending these subsidies seems unlikely. Without an extension, nearly 4 million Americans could lose coverage by 2026 due to unaffordable premiums.
The 2021 changes led to a surge in ACA enrollment, with 15.5 million people benefiting from subsidies across 32 states. The report adds that if the subsidies aren&#8217;t renewed, up to 15.4 million Americans could lose health coverage by 2030.
Another significant issue is Trump&#8217;s stance on Medicare. As president, he supported Medicare Advantage, a private insurer-run program that could eventually replace traditional, government-run Medicare.
The NPR report <a target="_blank" href="https://www.npr.org/sections/shots-health-news/2024/11/07/nx-s1-5183092/trump-election-2024-medicare-advantage" rel="noreferrer noopener">highlights</a> that critics argue that expanding private insurers could increase costs for taxpayers and limit care, with some beneficiaries finding it difficult to switch back to traditional Medicare.
Robert Berenson, a former government official, warned that traditional Medicare could &#8220;wither on the vine.&#8221;
Medicare Advantage grew with the 2003 legislation introducing a drug benefit and expanded private insurers&#8217; role in the program. Although private plans were expected to lower costs, they have been more expensive.
The report also says that in 2023, Medicare Advantage plans cost taxpayers about 6% — or $27 billion — more than traditional Medicare, though some research suggests they offer better care.
The future of healthcare policy in the U.S. will depend on the political dynamics in Congress and Trump&#8217;s second term.
With Republicans pushing for major changes to the ACA and Medicare, experts warn of significant shifts in how Americans access and pay for healthcare in the coming years.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a></li>
</ul>
Photo via Shutterstock

ALHC

CLOV

Laboratory Corporation Of America Holdings

Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

Deep-pocketed investors have adopted a bearish approach towards UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in UNH usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 52 extraordinary options activities for UnitedHealth Group. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 50% bearish. Among these notable options, 16 are puts, totaling $721,919, and 36 are calls, amounting to $2,134,986.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $480.0 to $650.0 for UnitedHealth Group during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for UnitedHealth Group's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of UnitedHealth Group's whale trades within a strike price range from $480.0 to $650.0 in the last 30 days. 
<h3>UnitedHealth Group Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730839752_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.05</td>
<td>$17.0</td>
<td>$17.0</td>
<td>$567.50</td>
<td>$278.8K</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">173</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$17.15</td>
<td>$17.1</td>
<td>$17.1</td>
<td>$565.00</td>
<td>$237.6K</td>
<td style="text-align: right;">187</td>
<td style="text-align: right;">158</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$14.95</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$565.00</td>
<td>$145.0K</td>
<td style="text-align: right;">148</td>
<td style="text-align: right;">241</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/08/24</td>
<td>$11.05</td>
<td>$10.7</td>
<td>$11.05</td>
<td>$562.50</td>
<td>$102.7K</td>
<td style="text-align: right;">50</td>
<td style="text-align: right;">127</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$19.3</td>
<td>$19.2</td>
<td>$19.3</td>
<td>$557.50</td>
<td>$88.5K</td>
<td style="text-align: right;">174</td>
<td style="text-align: right;">97</td>
</tr>
</tbody>
</table>

<h3>About UnitedHealth Group</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<h3>Where Is UnitedHealth Group Standing Right Now?</h3>
<ul>
<li>With a trading volume of 1,471,322, the price of UNH is up by 1.84%, reaching $568.04.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
<h3>What Analysts Are Saying About UnitedHealth Group</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $637.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald persists with their Overweight rating on UnitedHealth Group, maintaining a target price of $644. 
&#x2A; Consistent in their evaluation, an analyst from Keybanc keeps a Overweight rating on UnitedHealth Group with a target price of $650. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for UnitedHealth Group, targeting a price of $650. 
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for UnitedHealth Group, targeting a price of $650. 
&#x2A; An analyst from RBC Capital persists with their Outperform rating on UnitedHealth Group, maintaining a target price of $595. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for UnitedHealth Group, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

A Closer Look at UnitedHealth Group's Options Market Dynamics

<a href="https://www.bloomberg.com/news/articles/2024-11-05/unitedhealth-unilaterally-cut-doctors-pay-for-er-mental-health-records-show" title="https://www.bloomberg.com/news/articles/2024-11-05/unitedhealth-unilaterally-cut-doctors-pay-for-er-mental-health-records-show">https://www.bloomberg.com/news/articles/2024-11-05/unitedhealth-unilaterally-cut-doctors-pay-for-er-mental-health-records-show</a>

'UnitedHealth Emails Reveal Tension Over Cuts To Doctor Pay; Documents Unsealed In Litigation With A Blackstone-Backed Physician Group Show Controversy Inside The Company Over Reducing Payment Rates' - Bloomberg News

Technology giant NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is set to join the Dow Jones Industrial Average on Nov. 8 replacing Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), a move predicted by several market experts to <a href="https://www.benzinga.com/top-stories/24/05/39011237/exclusive-nvidia-dow-jones-inclusion-a-matter-of-when-will-it-replace-intel">Benzinga months ago.</a>
Here's a look at what the Dow Jones Industrial Average inclusion means for Nvidia and why another addition to the index could be more important.
What Happened: Nvidia <a href="https://www.benzinga.com/markets/equities/24/11/41699259/nvidia-rides-ai-wave-to-replace-intel-on-dow-jones-industrial-average-ending-its-25-year-run">will replace Intel</a> in the Dow Jones Industrial Average, a move that may have been predicted by a 10-for-1 stock split by the tech giant earlier this year.
"Price wise, shares are at that elevated level where they have announced a split in the past. Rumor wise, a stock split would make shares more attractive to be added to the Dow Jones Industrial Average," Freedom Capital Markets Chief Strategist Jay Woods said before the split was announced.
Woods told Benzinga Nvidia was a prime candidate to be included in the Dow Jones Industrial Average, which is tracked by the SPDR Dow Jones Industrial Average ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>).
"When you're the face of the next wave of growth in technology, that being AI, that being the chipmaker, that to me says you should be represented in the Dow Jones Industrial Average," Woods previously told Benzinga.
Launched in 1896, the <a href="https://www.benzinga.com/topic/dow-jones-industrial-average">Dow Jones Industrial Average</a> is a well-known stock market index that includes 30 blue-chip U.S. companies. The index often changes to include the best barometers of American growth.
One of the key differences between the Dow Jones Industrial Average and other market indexes like the S&amp;P 500 is the Dow is price-weighted and does not account for changes in market capitalization.
This means that company's that have higher share prices have larger weightings than those with smaller stock prices. So while Nvidia's stock split may have helped the company get into the index, it will now hurt the company's position in the index.
Based on data from <a href="https://www.slickcharts.com/dowjones">Slickcharts</a>, Nvidia would be the 21st largest company by weighting in the index if it were added today. The stock would position after Chevron ($153.33) and ahead of 3M Co ($126.94) with a price of $138.76 at the time of writing. Nvidia would have an estimated weighting of between 1.98% and 2.38% based on the current weighting of 3M and Chevron respectively.
Compare that to UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), currently the largest weighting in the Dow Jones Industrial Average at $556.81 and 8.8%.
Intel, which is being replaced by Nvidia, is currently ranked last in the index with a price of $22.54 and weighting of 0.36%.
As one of the largest companies in the world, Nvidia is the second largest weighting in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 Index, representing 6.8% of assets in the ETF. Nvidia is also the second largest weighting in the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>), which tracks the tech sector, with the stock having a weighting of 14.25%.
Are you buying when the CEOs of the Magnificent 7 are selling?Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a>
Another Dow Index Addition: While investors are excited about Nvidia joining the Dow Jones Industrial Average, they might want to look at Sherwin-Williams Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>), which will have a large weighting in the index and see heavier buying from ETFs that cover the index.
Sherwin-Williams has a current share price of $372.97, which will give the company a higher weighting in the index. The stock would currently rank sixth in the index between Caterpillar ($377.72) and Amgen ($317.75). If Sherwin-Williams were added today, the stock would have an estimated weighting of between 4.97% and 5.91%.
Sherwin-Williams is replacing Dow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) in the index, which currently ranks 28th with a price of $48.10 and a weighting of 0.76%.
The new weightings will depend on prices ahead of the Nov. 8 changes and also be impacted by two of the smaller holdings exiting the index.
Why It's Important: Intel has been a member of the Dow Jones Industrial Average since 1999 but has lagged in stock performance in recent years.
Nvidia is more relevant than Intel and used by the biggest companies, Woods previously told Benzinga.
"The growth is there, the story is there, and now the price is there," Woods said.
Benzinga's "PreMarket Prep" co-host Dennis Dick also predicted Nvidia replacing Intel in the index earlier this year.
"I'd expect this announcement sometime in the summer. I don't think it's a matter of ‘if' NVDA goes into the Dow, I think it's now a matter of ‘when,'" Dick said.
Nvidia shares are up 188.1% year-to-date in 2024 and up 2,573.6% over the past five years. Intel stock is down 52.9% year-to-date in 2024 and down 61.4% over the past five years.
Sherwin-Williams stock is up 22.3% year-to-date in 2024 and up 92.5% over the past five years. Dow stock is down 14.0% year-to-date in 2024 and down 15.0% over the last five years.
The negative performance for Intel and Dow may explain why the Dow Jones Industrial Average has underperformed the S&amp;P 500 index. The Dow Jones Industrial Average ETF is up 11.1% year-to-date and up 51.2% over the past five years. Compare that to the SPY, which is up 20.8% year-to-date and up 84.9% over the past five years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

ETFs

SPDR Dow Jones Industrial Average ETF Trust

INTC

NVDA

Nvidia Joining Dow Jones Industrial Average: Where Tech Giant Ranks In The Index, Why Sherwin-Williams Addition Could Be More Important

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 20 years by 5.85% on an annualized basis producing an average annual return of 14.17%. Currently, UnitedHealth Group has a market capitalization of $519.85 billion. 
Buying $100 In UNH: If an investor had bought $100 of UNH stock 20 years ago, it would be worth $1,416.61 today based on a price of $562.96 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730320221_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 20 Years

In today's rapidly changing and highly competitive business world, it is vital for investors and industry enthusiasts to carefully assess companies. In this article, we will perform a comprehensive industry comparison, evaluating UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) against its key competitors in the Health Care Providers &amp; Services industry. By analyzing important financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>UnitedHealth Group Background</h3>
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>UnitedHealth Group Inc</td>
<td>36.55</td>
<td>5.20</td>
<td>1.34</td>
<td>4.79%</td>
<td>$7.67</td>
<td>$21.06</td>
<td>6.61%</td>
</tr>
<tr>
<td>Centene Corp</td>
<td>10.47</td>
<td>1.12</td>
<td>0.20</td>
<td>4.22%</td>
<td>$2.0</td>
<td>$4.43</td>
<td>5.92%</td>
</tr>
<tr>
<td>Molina Healthcare Inc</td>
<td>16.44</td>
<td>3.87</td>
<td>0.48</td>
<td>6.78%</td>
<td>$0.51</td>
<td>$1.19</td>
<td>20.96%</td>
</tr>
<tr>
<td>HealthEquity Inc</td>
<td>72.60</td>
<td>3.53</td>
<td>6.98</td>
<td>1.68%</td>
<td>$0.11</td>
<td>$0.2</td>
<td>23.15%</td>
</tr>
<tr>
<td>Progyny Inc</td>
<td>24.83</td>
<td>3.10</td>
<td>1.38</td>
<td>3.21%</td>
<td>$0.02</td>
<td>$0.07</td>
<td>8.85%</td>
</tr>
<tr>
<td>Average</td>
<td>31.08</td>
<td>2.9</td>
<td>2.26</td>
<td>3.97%</td>
<td>$0.66</td>
<td>$1.47</td>
<td>14.72%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>After examining UnitedHealth Group, the following trends can be inferred: 
<ul>
<li>
Notably, the current Price to Earnings ratio for this stock, 36.55, is 1.18x above the industry norm, reflecting a higher valuation relative to the industry.
</li>
<li>
The elevated Price to Book ratio of 5.2 relative to the industry average by 1.79x suggests company might be overvalued based on its book value.
</li>
<li>
With a relatively low Price to Sales ratio of 1.34, which is 0.59x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The company has a higher Return on Equity (ROE) of 4.79%, which is 0.82% above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.
</li>
<li>
Compared to its industry, the company has higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.67 Billion, which is 11.62x above the industry average, indicating stronger profitability and robust cash flow generation.
</li>
<li>
With higher gross profit of $21.06 Billion, which indicates 14.33x above the industry average, the company demonstrates stronger profitability and higher earnings from its core operations.
</li>
<li>
The company's revenue growth of 6.61% is significantly below the industry average of 14.72%. This suggests a potential struggle in generating increased sales volume.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730300423_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
By evaluating UnitedHealth Group against its top 4 peers in terms of the Debt-to-Equity ratio, the following observations arise:
<ul>
<li>
Among its top 4 peers, UnitedHealth Group has a higher debt-to-equity ratio of 0.84.
</li>
<li>
This suggests a greater reliance on debt financing, which can expose the company to increased financial risk and potential volatility.
</li>
</ul>
<h3>Key Takeaways</h3>
For UnitedHealth Group, the PE, PB, and PS ratios indicate high valuation compared to peers in the Health Care Providers &amp; Services industry. This suggests potential overvaluation based on these metrics. On the other hand, the high ROE, EBITDA, and gross profit, along with low revenue growth, highlight strong profitability and operational efficiency relative to industry competitors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Analysis: UnitedHealth Group Versus Competitors In Health Care Providers &amp; Services Industry

UnitedHealth Group: Preparing For December Investor Day, Buy Reiterated

UnitedHealth: Navigating Policy Uncertainty Well, Solid EPS Growth Ahead

UnitedHealth Group: Now A Fairly Valued Dividend-Growth Machine

Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC

U.S. Managed Care Q3 2024 Earnings Recap: Medicaid/Medicare Costs Mount

UnitedHealth wins Star Ratings lawsuit against Medicare

Here are the top industries and stocks that were impacted by the comments, actions and policies of President-elect Trump this week compiled by The ...

Trump Weekly: Trump looks to drop EV tax credit, fuel-efficiency requirements

Barclays analyst Andrew Mok CFA maintained a Buy rating on UnitedHealth (UNH – Research Report) today and set a price target of $603.00. The compan...

Barclays Reaffirms Their Buy Rating on UnitedHealth (UNH)

UnitedHealth win in CMS case a positive for Humana, sector: Leerink

Tracking Ruane, Cunniff, & Goldfarb's Portfolio: Q3 2024 Update

ABBV

AMGN

AMTM

ASHTF

BIIB

BKKT

CACC

CHTR

CNSWF

CRKN

ERFSF

FWONA

FWONB

FWONK

GILD

GOOG

GOOGL

HNDAF

HUBB

INTU

LBRDA

LBRDB

LBRDK

LBRDP

LMGIF

MBGAF

MBGYY

MRNA

NSANF

NSANY

RYCEY

SCHW

SNYNF

STLA

TSLA

TSMWF

UMGNF

VWAGY

VWAPY

Press Releases

UNITEDHEALTH GROUP INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of UnitedHealth Group Incorporated - UNH

UnitedHealth Group and Goodwill® Partner to Expand Career Pathways Training to Foster Healthier Communities

UNITEDHEALTH GROUP INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of UnitedHealth Group Incorporated - UNH

UnitedHealth Group Announces Earnings Release Date

UnitedHealthcare Community Plan of New Mexico invests $250,000 to provide integrated health care services to K-12 students

UNITEDHEALTH ALERT: Bragar Eagel & Squire, P.C. is Investigating UnitedHealth Group Incorporated on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

UnitedHealthcare Commits $335,000 to Idaho Organizations To Expand Health Care Workforce and Access To Care

Comments

UnitedHealth Group

空売り

UnitedHealth Group (NYSE:UNH) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル